{"id":"plasma-derived-antithrombin","safety":{"commonSideEffects":[{"rate":"null","effect":"Hemorrhage"},{"rate":"null","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL1201554","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This mechanism of action is based on the protein's ability to bind to and inactivate key enzymes in the coagulation cascade, thereby preventing the formation of blood clots. Antithrombin has a high affinity for thrombin and other coagulation factors, making it an effective inhibitor of coagulation.","oneSentence":"Plasma-derived antithrombin is a protein that inhibits the coagulation cascade by binding to and neutralizing thrombin and other coagulation factors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:46.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of deep vein thrombosis and pulmonary embolism in patients undergoing major orthopedic surgery"}]},"trialDetails":[{"nctId":"NCT06096116","phase":"PHASE3","title":"Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass","status":"RECRUITING","sponsor":"Octapharma","startDate":"2024-08-21","conditions":"Acquired Antithrombin Deficiency","enrollment":120},{"nctId":"NCT00319228","phase":"PHASE2, PHASE3","title":"Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grifols Biologicals, LLC","startDate":"2006-01","conditions":"Antithrombin III Deficiency","enrollment":30},{"nctId":"NCT01384903","phase":"PHASE3","title":"An Open-label Study of KW-3357","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2011-06","conditions":"Disseminated Intravascular Coagulation (DIC)","enrollment":221},{"nctId":"NCT01698567","phase":"PHASE1","title":"Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)","status":"TERMINATED","sponsor":"University of Rochester","startDate":"2012-07","conditions":"Congenital Heart Disease","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Plasma-derived antithrombin","genericName":"Plasma-derived antithrombin","companyName":"Kyowa Kirin Co., Ltd.","companyId":"kyowa-kirin-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Plasma-derived antithrombin is a protein that inhibits the coagulation cascade by binding to and neutralizing thrombin and other coagulation factors. Used for Prevention of deep vein thrombosis and pulmonary embolism in patients undergoing major orthopedic surgery.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}